[1] LAFARO K J,DEMIRJIAN A N,PAWLIK T M.Epidemiology of hepatocellular carcinoma[J]. Surg Oncol Clin N Am,2015,24(1):1-17. [2] 王学军,李永国. 原发性肝癌的手术治疗进展[J]. 中国现代手术学杂志,2001,5(4):313-316. [3] 范芯铷,刘铭佳,王庆,等. 原发性肝癌的发病机制及治疗进展[J]. 肝脏,2023,28(4):391-392. [4] 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 中华外科杂志,2022,60(4):273-309. [5] 陈健忠,贾长库. 原发性肝癌手术治疗进展[J]. 浙江医学,2023,45(4):439-443. [6] LISMAN T,PORTE R J.Rebalanced hemostasis in patients with liver disease:evidence and clinical consequences[J]. Blood,2010,116(6):878-885. [7] 莫琴,黄宇闻,刘鸿,等. LED白光的亚甲蓝光化学法血浆病毒灭活研究[J]. 临床输血与检验,2024,26(4):463-469. [8] 黄佳丽,刘正婷,陈尚良,等. 亚甲蓝光病毒灭活血浆的研究进展[J]. 临床输血与检验,2021,23(2):268-272. [9] 李雪英,韩惠云,邱玉霞,等. 亚甲蓝光化学法病毒灭活对血浆主要质量指标的影响[J]. 临床输血与检验,2009, 11(2):159-160. [10] RUMGAY H,ARNOLD M,FERLAY J,et al.Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol,2022,77(6):1598-1606. [11] 刘青光,宋涛,王欢欢. 肝癌外科手术切除技术的再认识[J].中华消化外科杂志,2024,23(1):75-79. [12] 岳锦熙,万晓红,万林骏,等.肝脏切除围手术期凝血和纤溶分子标志物变化规律的研究[J].中国中西医结合急救杂志,2022,29(1):5. [13] MEJIA J C,PASKO J.Primary liver cancers:intrahepatic cholangiocarcinoma and hepatocellular carcinoma[J]. Surg Clin North Am,2020,100(3):535-549. [14] CAI H,ZHU X D,LI X L,et al.Future liver volume combined with platelet count predicts liver failure after major hepatectomy[J]. Surgeon,2022,20(6):e416-e422. [15] 雷光林,王淑英,刘志国. 原发性肝癌患者行肝切除术后输注新鲜冰冻血浆的临床疗效观察[J]. 胃肠病学和肝病学杂志,2014,23(10):1202-1203. [16] O'SHAUGHNESSY D F,ATTERBURY C,BOLTON MAGGS P,et al. Guidelines for the use of fresh-frozen plasma,cryoprecipitate and cryosupernatant[J]. Br J Haematol,2004,126(1):11-28. [17] LU Y,SUN G X,LIU X F,et al.Plasma transfusion in patients with cirrhosis in China:a retrospective multicenter cohort study[J]. Transfus Med Rev,2017, 31(2):107-112. [18] 太继琼. 冰冻血浆在临床中的应用分析[J]. 临床输血与检验,2012,14(3):237-238. [19] 李榕,陈火玲,钱献,等. 亚甲蓝/光照法病毒灭活血浆的制备及应用评价[J]. 临床输血与检验,2013,15(1):4-7. [20] 梁佩贤,招淑文,卓创近,等. 不同条件储存制备新鲜冰冻血浆对质量的影响[J]. 血栓与止血学,2022,28(6):904-907. [21] 席朝运,马春娅,张宏飞,等. 血浆输注过敏性输血反应发生机制及体外试验研究进展[J]. 中国实验血液学杂志, 2021,29(5):1662-1666. [22] 何欢,阙文君. 血浆输注的临床应用及管理研究进展[J]. 重庆医学,2023,52(12):1898-1902. [23] 曾科文,李海洋. 肝内胆管癌的诊疗进展[J]. 腹部外科, 2023,36(3):184-188. [24] RODRIGUES P M,OLAIZOLA P,PAIVA N A,et al.Pathogenesis of cholangiocarcinoma[J]. Annu Rev Pathol,2021,16:433-463. [25] 汪国营,何才华. 肝移植治疗肝内胆管癌的研究进展[J]. 器官移植,2023,14(6):789-796. [26] PASCHALIS GAVRIILIDIS, NATALIE M.BATH, TIMOTHY M.PAWLIK. The impact of lymphadenectomy on intrahepatic cholangiocarcinoma management and prognosis:a comprehensive review[J]. Hepatoma Research, 2023, 9(6):27-34. [27] KANWAL F,KRAMER J R,MAPAKSHI S,et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease[J]. Gastroenterology,2018, 155(6):1828-1837.e2. [28] RICH N E,MURPHY C C,YOPP A C,et al.Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma[J]. Aliment Pharmacol Ther,2020,52(4):701-709. |